Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)

NCT00295789CompletedPHASE3INTERVENTIONAL

Summary

Key Facts

Lead Sponsor

Haruhiko Fukuda

Enrollment

253

Start Date

2006-02-01

Completion Date

2011-11-01

Study Type

INTERVENTIONAL

Official Title

A Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Carboplatin in Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)

Interventions

chemotherapy: Paclitaxel/Cisplatinchemotherapy: Paclitaxel/Carboplatin

Conditions

Uterine Cervical Neoplasms

Eligibility

Age Range

20 Years – 75 Years

Sex

FEMALE

Inclusion Criteria:

1. histologically proven uterine cervical cancer
2. squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the uterine cervix
3. one of the followings, 1)primary stage Ⅳb cervical cancer, 2)the first relapse or persistent cervical cancer after curative first line treatments, 3)the second relapse or persistent cervical cancer after curative second line treatments including radiation, systemic chemotherapy, hormonal therapy, or vaccination therapy for the first relapse
4. Patients may have been previously treated with less than 50 Gy of palliative radiation therapy
5. Patients have received no prior treatment or a certain interval must have elapsed from the last administration of previous treatments including palliative radiation therapy
6. one of the followings, 1)There is at least one metastatic lesion outside the pelvic cavity except paraaortic LN and/or inguinal LN, 2)There is no metastatic lesion outside the pelvic cavity except paraaortic LN and/or inguinal LN and some of the lesions have been irradiated, 3)All lesions are localized inside the pelvic cavity, and some of them have been irradiated
7. no prior surgical therapy for metastatic lesions of the lung or inside the pelvic cavity
8. no bilateral hydronephrosis
9. no prior chemotherapy including more than two platinum-containing regimens
10. no prior chemotherapy including taxane
11. age: 20 to75 years
12. PS: 0-2
13. ANC ≧1,500 /mm3, Plt≧10.0×104/mm3, T-bil≦1.5 mg/dl, GOT(AST)≦100IU/l, sCre ≦1.2 mg/dl, Ccr≧50ml/min in using the Cockcroft-Gault equation, and normal ECG
14. written informed consent

Exclusion Criteria:

1. patients who have some neurologically functional disorder
2. symptomatic CNS metastasis
3. hypersensitive to alcohol
4. active infection
5. HBs antigen positive
6. uncontrollable hypertension
7. history of myocardiac infarction within six months
8. unstable angina
9. uncontrollable diabetes
10. Patients with a concomitant or prior invasive malignancy (except intramucosal malignancy which are curable with local therapy) who have had any evidence of the disease within the last 5 years
11. women during pregnancy or breast-feeding
12. patients with psychiatric illness
13. patients who have been treated with the systemic steroids medication

Outcome Measures

Primary Outcomes

overall survival

Time frame: During the study conduct

Secondary Outcomes

progression-free survival

Time frame: During the study conduct

response rate

Time frame: During the study conduct

adverse events

Time frame: During the study conduct

severe adverse events

Time frame: During the study conduct

proportion of periods of non-hospitalization to those of the planned treatment

Time frame: 18 weeks

Locations

Aichi Cancer Center Hospital, Nagoya,Chikusa-ku,Kanokoden,1-1, Japan

Nagoya Medical Center, Nagoya,Naka-ku,Sannomaru,4-1-1, Japan

National Hospital Organization Shikoku Cancer Center, Matsuyama,Horinouchi,13, Japan

Kyushu University Hospital, Fukuoka,Higashi-ku,Maidashi,3-1-1, Japan

National Kyushu Cancer Center, Fukuoka,Minami-ku,Notame,3-1-1, Japan

Kurume University School of Medicine, Kurume, Asahi-machi, 67, Japan

Gunma Prefectural Cancer Center, Ota,Takabayashi-nishi-cho,617-1, Japan

National Hospital Organization Kure Medical Center Chugoku Cancer Center, Kure,Aoyama-cho,3-1, Japan

Hokkaido University Hospital, North-14 West-5 Kita-ku,Sapporo, Japan

Sapporo Medical University, S-1,W-16,Chuo-ku,Sapporo, Japan

Hyogo Medical Center for Adults, Akashi,Kitaouji-cho,13-70, Japan

Institute of Clinical Medicine,Tsukuba University Hospital, Tsukuba,Tennodai,1-1-1, Japan

Kagoshima City Hospital, Kagoshima,Kajiya-cho,20-17, Japan

Tohoku University Hospital, Sendai,Aoba-ku,Seiryo-machi,1-1, Japan

Sinshu University, Matsumoto,Asahi,3-1-1, Japan

Nagaoka Red Cross Hospital, Nagaoka,Terashima-cho,297-1, Japan

Niigata Cancer Center Hospital, Niigata,Kawagishi-cho,2-15-3, Japan

Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka,Higashinari-ku,Nakamichi,1-3-3, Japan

Osaka City General Hospital, Osaka,Miyakojima-ku,Miyakojimahondori,2-13-22, Japan

Kinki University School of Medicine, Osaka-Sayama,Ohno-higashi,377-2, Japan

Faculty of Medicine, Saga University, Saga,Nabeshima,5-1-1, Japan

Saitama Medical Center, Saitama Medical School, Kawagoe,Komoda,1981, Japan

Saitama Cancer Center, Kita-adachi,Ina,Komuro,818, Japan

National Defense Medical College, Tokorozawa,Namiki,3-2, Japan

Juntendo University School of Medicine, Bunkyo-ku,Hongo,3-1-3, Japan

The University of Tokyo Hospital, Bunkyo-ku,Hongo,7-3-1, Japan

National Cancer Center Hospital, Chuo-ku,Tsukiji,5-1-1, Japan

Cancer Institute Hospital, Koto-ku,Ariake,3-10-6, Japan

Jikei University Hospital, Minato-ku,Nishishinbashi,3-25-8, Japan

Tottori University School of Medicine, Yonago,Nishimachi,36-1, Japan